Algorics Releases New Version of Analytics Platform
Acuity now features enhanced site monitoring support, full tracking of insights into actions, and Japanese localization
Houston, TX - Algorics, a provider of cloud-based innovative clinical analytics solutions and software for the global life sciences industry, today announced the release of Acuity version 1.4.
Key features of the new release include:
Decision Factory – Site monitoring recommendation module
- The recent addendum to ICH E6 R2 recommends that the “Detection of deviations from the predefined quality tolerance limits should trigger an evaluation to determine if action is needed” Decision Factory provides statistical algorithm based ranking of the site risk based on how the site performs across study specific KRI thresholds. The sponsor also has control to change thresholds and KRIs during the study; all tracked in our audit trail.
Action Center – End-to-end workflow within Acuity to track insights into actions
- Teams can take advantage of the Action Center module to record findings captured while reviewing analytics in Acuity, assign to a team member with a priority level, and track the conversation history until the item is resolved. The traceability of insights to actions supplements the recent ICH E6 R2 need for reporting the outcomes of centralized monitoring.
Localization & Japanese support
- The Acuity analytics platform is now available with a Japanese language interface enabling Japanese users to monitor the data, and see visualizations in Kanji, as well as running all administrative functions in their chosen language. Global companies can bring together both Japanese and English language data in one environment.
Nithiya Ananthakrishnan, CEO of Algorics commented, “Our customers and partners feedback has directly driven the development of the latest version of Acuity. We understand that clinical data analytics is not just dashboard reporting but the need for end-to-end workflow that transforms insights to decisions and actions. This eliminates the risk of losing track of actions that should be taken post data analysis."
Rob Nichols, CCO of Algorics added “The Japanese localization enables us to support our customers and industry partners with a presence in Japan. We look forward to building an increased presence in the region and demonstrating the new and enhanced features.”
Meet us in March 2017 and find out more about the Acuity analytics platform:
March 21-22
Outsourcing in Clinical Trials South East 2017 - Cary, NC, USA
Clinical Data Integration & Management - Princeton, NJ, USA
March 23-24
OmniComm Innovation Forum Europe 2017 - Barcelona, Spain
March 26-31
SQA Annual Meeting - National Harbor, ND, USA
March 29-31
DIA Euromeeting - Glasgow, UK
About Algorics
Algorics brings together a team of highly experienced software and life sciences professionals, united behind a single goal: to provide innovative clinical analytics solutions and software to the global life sciences industry
with consistent and reliable quality. Algorics has a truly international presence, with offices in Doylestown, PA, Houston, TX (USA), London (UK) and Bangalore (India). Learn more by visiting www.algorics.com or
stay updated by following us on social media: Twitter, Facebook, LinkedIn
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
